Shingrix is GSK's brand name for zoster vaccine recombinant, adjuvanted, a two-dose vaccine approved by the FDA in 2017 to prevent shingles (herpes zoster) and its most common complication, postherpetic neuralgia. The Advisory Committee on Immunization Practices recommends Shingrix for all adults age 50 and older, and for adults 19 and older who are or will be immunocompromised due to disease or therapy. Each dose is given as an intramuscular injection, typically in the upper arm, with the second dose administered 2 to 6 months after the first, or 1 to 2 months apart for immunocompromised patients who need an accelerated schedule. Unlike the older live-virus shingles vaccine Zostavax, which was discontinued in the United States in November 2020, Shingrix is a non-live recombinant subunit vaccine combined with GSK's proprietary AS01B adjuvant, and clinical trials showed it is more than 90% effective at preventing shingles across all age groups, including adults 70 and older.
GSK's 2026 private-sector list price for Shingrix is $215.51 per dose, according to the CDC Adult Vaccine Price List updated January 2026. Pharmacies and physician offices mark that acquisition cost up when billing cash-paying patients, which is why the retail cash price without insurance runs $220 to $315 per dose, or roughly $440 to $630 for the required two-dose series. What you actually pay depends almost entirely on your coverage type rather than the pharmacy you choose. Medicare Part D pays $0 per dose for essentially all beneficiaries, 96% of commercially insured patients also pay $0, and Medicaid copays run under $5 per dose in most states. The only patients who routinely face the full cash price are the uninsured, and GSK's Vaccines Patient Assistance Program exists specifically to close that gap for income-eligible applicants.
The Inflation Reduction Act of 2022 affects Shingrix through a different mechanism than the headline Medicare drug-price-negotiation program. Section 11401 of the law eliminated all Medicare Part D cost-sharing for ACIP-recommended adult vaccines, including Shingrix, effective January 1, 2023, a change that research published in 2025 found meaningfully increased shingles vaccination rates among Medicare Part D enrollees. Shingrix itself was never selected for the separate Medicare drug-price-negotiation program that set Maximum Fair Prices for 10 chronic-disease drugs like Eliquis and Jardiance starting January 1, 2026; that program targets high Part B and Part D spend on prescription drugs, not preventive vaccines administered under a benefit that already carries no cost-sharing. Medicare beneficiaries who want more detail on how their coverage works can review Medicare's shingles vaccine coverage page, and anyone comparing GSK's income thresholds below against their own state's Medicaid income limits should check current figures before applying.
What Shingrix Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same shingrix can cost many times more at a hospital than at your local pharmacy:
2026 Shingrix Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $220 - $315/dose ($440 - $630 for both doses) | 2026 cash price without insurance; CDC private-sector price is $215.51/dose |
| Medicare Part D (2026) | $0/dose | Covered at no cost since 2023-01-01 under the Inflation Reduction Act's vaccine cost-sharing elimination |
| Commercial insurance (in-network) | $0 for about 96% of plans | ACA preventive-services mandate requires no-cost coverage for ACIP-recommended vaccines in-network |
| Medicaid | $0 - $5/dose | Covered in most states with no or nominal cost-sharing; rules vary by state Medicaid income limits and expansion status |
| GSK Vaccines Patient Assistance Program | $0/dose for eligible uninsured applicants | Income at or below 300% of the federal poverty level; not available to anyone enrolled in Medicare or other insurance |
Cash prices reflect 2026 GoodRx, SingleCare, and CDC Vaccine Price List data. Actual charges vary by pharmacy, provider, and ZIP code.
Source: CDC Adult Vaccine Price List (2026), CMS Medicare Part D vaccine coverage guidance, GoodRx, SingleCare
Why Hospitals Charge So Much
Hospital outpatient departments and emergency rooms occasionally administer Shingrix, usually when a patient is already being seen for another reason and a nurse or pharmacist offers the vaccine, or when a patient specifically requests it during a hospital stay. In that setting, the charge can run $450 to $900 per dose, several times higher than the $215.51 CDC private-sector price, because hospitals layer facility fees, nursing administration charges, and overhead markups on top of the vaccine's acquisition cost. The same dose that costs $220 to $315 at a retail pharmacy can show up on a hospital itemized bill at nearly triple that amount. For Medicare and commercial-insurance patients, this markup rarely matters because Shingrix is a $0 cost-sharing vaccine regardless of where it is given, but uninsured patients billed in a hospital setting can face the full facility rate unless they push back.
Ask for an itemized bill and the National Drug Code before paying a hospital Shingrix charge above $315 per dose. The NDC for Shingrix's 10-pack single-dose vial is 58160-0823-11, and comparing that line item to the CDC's published private-sector price of $215.51 per dose is the fastest way to spot an inflated facility markup. Uninsured patients who receive Shingrix in a hospital setting should ask the billing office about a self-pay discount or a charity-care policy before assuming the sticker price is final, and should also ask whether the hospital's outpatient pharmacy can refer them to GSK's Vaccines Patient Assistance Program for future doses instead of paying facility rates twice. Patients with Medicare or commercial insurance who are billed anything above $0 in a hospital setting should specifically ask the billing office to confirm Shingrix was routed through the Part D pharmacy benefit or the ACA preventive-services benefit rather than the standard inpatient facility fee schedule, since that routing error is the most common reason a $0 vaccine turns into a several-hundred-dollar hospital charge.
Patient Assistance Programs
GSK, the manufacturer of Shingrix, runs a Vaccines Patient Assistance Program specifically for adults who have no insurance coverage for vaccines at all. Because Medicare Part D and nearly all commercial insurance already cover Shingrix at $0 under the rules above, this program exists almost entirely for the uninsured.
Patient assistance programs for Shingrix| Manufacturer program | Cost / Benefit | How to apply |
|---|
| GSK Vaccines Patient Assistance Program | Free Shingrix for uninsured US adults with household income at or below 300% of the federal poverty level | gskpaf.org/gsk/vaccines-patient-assistance |
| NeedyMeds Vaccine and Drug Discount Card | Variable discount accepted at most US pharmacies; does not require income verification | needymeds.org |
| State and local health department adult immunization clinics | Free or reduced-cost Shingrix at many county health departments and community health centers, particularly for uninsured and underinsured adults | vaccines.gov |
Federal anti-kickback rules generally bar manufacturer copay cards from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries, but that issue rarely comes up with Shingrix because GSK does not offer a manufacturer coupon for it. Medicare beneficiaries do not need any assistance program: Part D already covers Shingrix at $0 per dose under the Inflation Reduction Act. The GSK Vaccines Patient Assistance Program goes further and explicitly excludes anyone enrolled in Medicare, Medicaid, or private insurance; it is reserved for adults with no third-party vaccine coverage at all.
Source: GSK Patient Assistance Foundation, NeedyMeds.org, Vaccines.gov
Medicare Part D
Medicare Part D has covered Shingrix at $0 out-of-pocket for every enrollee since January 1, 2023, under Section 11401 of the Inflation Reduction Act of 2022, which eliminated deductibles, copays, and coinsurance for all ACIP-recommended adult vaccines. That protection applies regardless of which Part D plan you have, what formulary tier the plan would otherwise assign to Shingrix, and where you are in your benefit year; the vaccine does not count toward your deductible or your $2,100 annual out-of-pocket cap for 2026 because you are never charged for it in the first place. Before 2023, Medicare beneficiaries could face deductibles and coinsurance of $50 or more per dose for Shingrix, which research tied directly to lower vaccination rates among seniors; the elimination of that cost-sharing is one of the more consequential, if less publicized, drug-cost provisions inside the Inflation Reduction Act.
Original Medicare Part B does not cover Shingrix because CMS classifies most non-influenza, non-pneumococcal adult vaccines under Part D rather than Part B. That distinction matters because it drives how claims are processed: Shingrix should be billed through your Part D pharmacy benefit, whether you pick it up at a retail pharmacy or receive it in your doctor's office, not through the medical benefit used for most doctor-administered drugs. A common and correctable error happens when a physician's office bills Shingrix under the medical benefit instead of routing the claim to your Part D plan, which can generate an incorrect out-of-pocket charge for something that should cost $0. Patients who are billed this way should ask the office to run the claim as a pharmacy transaction through the patient's stand-alone Part D plan or Medicare Advantage plan's drug benefit instead of the medical claims system, since that single correction typically resolves the charge without an appeal.
Medicare Advantage plans that include Part D prescription drug coverage must follow the same $0 cost-sharing rule for Shingrix as standalone Part D plans. If a Medicare Advantage or Part D plan tries to charge a copay, coinsurance, or deductible for Shingrix in 2026, that charge is very likely a billing error rather than a legitimate cost, and you should ask the pharmacy to resubmit the claim before paying. Medicare Advantage members should also confirm that their plan's network pharmacy or clinic actually stocks Shingrix, since supply gaps at smaller in-network pharmacies sometimes lead staff to incorrectly tell patients the vaccine is not covered rather than referring them to a pharmacy that carries it, which is a common source of confusion rather than an actual coverage denial.
Common Shingrix Billing Errors
If you were charged anything more than $0 for Shingrix with Medicare Part D, or more than a small copay with commercial insurance or Medicaid in 2026, check for these issues before paying. Reviewing your bill with a tool like CoveredUSA's medical bill analyzer can help you spot which of these applies.
- Shingrix billed under the medical/Part B benefit instead of the Part D pharmacy benefit, which can generate a charge even though Part D coverage is $0. Ask the provider's billing office to resubmit through Part D.
- Second dose billed as an out-of-network or non-covered service because it was given at a different pharmacy or provider than the first dose. Coverage follows the patient, not the location, as long as the provider is in-network.
- A separate administration fee charged on top of the vaccine cost. Part D and most commercial plans bundle the administration fee into the $0 cost-sharing; a standalone administration charge is usually incorrect.
- Second dose denied because it was given less than 4 weeks after the first. ACIP's minimum interval is 4 weeks; anything shorter can trigger an automatic denial that requires a corrected claim, not a cash payment.
- Uninsured patients charged full retail price without being told about the GSK Vaccines Patient Assistance Program, which can provide Shingrix free to eligible applicants.
- Inpatient or emergency department charges of $450 to $900 per dose when the CDC's published private-sector price is $215.51 per dose. Request an itemized bill and the NDC before paying a hospital markup like this.
Frequently Asked Questions
Is there a generic or biosimilar version of Shingrix?
No. Shingrix has no generic or biosimilar equivalent as of 2026. GSK's core patents on the vaccine are expected to run through roughly 2029 in the United States, and vaccines do not follow the same fast generic pathway as small-molecule pills. The older shingles vaccine, Zostavax, used a live-virus technology and was discontinued in the US in November 2020 because Shingrix proved significantly more effective, but Zostavax was never a generic version of Shingrix and is not an interchangeable substitute.
How do I apply for the GSK Patient Assistance Program for Shingrix?
Ask your doctor's office or pharmacy to register as a GSK Patient Assistance Program provider, then have them submit the Vaccines Patient Assistance Program application on your behalf, either online at gskpaf.org or by fax to 1-855-474-3063. You will need proof of household income, proof that you have no insurance covering vaccines, and valid ID. Approval typically covers free Shingrix doses for up to 12 months, shipped directly to your provider's office. This program is only for adults with no third-party vaccine coverage at all; it explicitly excludes anyone enrolled in Medicare.
Do I need a Shingrix savings card or coupon if I have Medicare?
No. GSK does not even offer a manufacturer copay card for Shingrix because it is not necessary: Medicare Part D has covered Shingrix at $0 per dose for every enrollee since January 1, 2023, under the Inflation Reduction Act's elimination of adult-vaccine cost-sharing. Federal anti-kickback rules would bar Medicare beneficiaries from using a manufacturer coupon anyway. If you see a charge on Medicare for Shingrix in 2026, it is almost certainly a billing error, not a legitimate cost, and you should ask your pharmacy to resubmit the claim through Part D.
What if my insurance denies coverage for Shingrix?
Request a written denial notice explaining the exact reason, then ask your pharmacy or provider to confirm Shingrix was billed through the correct benefit; Medicare claims should route through Part D, not the medical benefit. If the denial stands, file a formal appeal within 60 days, citing the ACIP recommendation for your age or risk group and, for Medicare or ACA plans, the vaccine's cost-sharing exemption. Escalate to an independent external review or your state Department of Insurance if the internal appeal fails. Uninsured patients can apply to the GSK Vaccines Patient Assistance Program instead.
Does the IRA negotiated Maximum Fair Price apply to Shingrix?
No. Shingrix is not one of the drugs selected for Medicare's price-negotiation program, which set Maximum Fair Prices for 10 chronic-disease drugs like Eliquis and Jardiance effective January 1, 2026. A different section of the same law, the Inflation Reduction Act of 2022, does affect Shingrix: it eliminated all Medicare Part D cost-sharing for ACIP-recommended adult vaccines starting January 1, 2023, which is why Shingrix already costs Medicare beneficiaries $0 per dose without needing a negotiated price at all.
What does Shingrix cost without insurance at the pharmacy counter in 2026?
Cash prices without insurance run $220 to $315 per dose in 2026, or roughly $440 to $630 for the full two-dose series, depending on the pharmacy. Costco tends to run near $258 to $261 per dose, Walmart's cash price is closer to $230, and CVS and Walgreens typically fall between $268 and $274 per dose before any coupon. The CDC's published private-sector price, which reflects what providers pay GSK before markup, is $215.51 per dose. Uninsured patients earning at or below 300% of the federal poverty level should apply for the GSK Vaccines Patient Assistance Program instead of paying cash.
Do I qualify for the GSK Vaccines Patient Assistance Program?
You qualify if you are 18 or older, live in the US or Puerto Rico, have no insurance coverage for vaccines at all, are not enrolled in Medicare, and your household income is at or below 300% of the federal poverty level, which is $47,880 for a single person and $99,000 for a household of four in 2026. Applications must be submitted by a registered healthcare provider on your behalf, not directly by the patient. Anyone with Medicare, Medicaid, or private insurance already has $0 or near-$0 coverage for Shingrix and does not need this program.
What is the difference between Shingrix and the older shingles vaccine Zostavax?
Shingrix is a two-dose recombinant subunit vaccine with GSK's AS01B adjuvant, over 90% effective at preventing shingles across all age groups. Zostavax was a single-dose live-attenuated vaccine made by Merck that was roughly 51% effective and lost effectiveness quickly with age; it was discontinued in the United States in November 2020. If you previously received Zostavax, the CDC still recommends getting the two-dose Shingrix series for stronger, longer-lasting protection, and Medicare Part D and most commercial insurance cover it at $0 in 2026 regardless of your Zostavax history.
